MA44484A - Biomarqueurs de protéinopathies et utilisations associées - Google Patents
Biomarqueurs de protéinopathies et utilisations associéesInfo
- Publication number
- MA44484A MA44484A MA044484A MA44484A MA44484A MA 44484 A MA44484 A MA 44484A MA 044484 A MA044484 A MA 044484A MA 44484 A MA44484 A MA 44484A MA 44484 A MA44484 A MA 44484A
- Authority
- MA
- Morocco
- Prior art keywords
- proteinopathy
- biomarkers
- associated uses
- proteinopathy biomarkers
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313638P | 2016-03-25 | 2016-03-25 | |
| US201662372523P | 2016-08-09 | 2016-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44484A true MA44484A (fr) | 2019-01-30 |
Family
ID=58547821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044484A MA44484A (fr) | 2016-03-25 | 2017-03-24 | Biomarqueurs de protéinopathies et utilisations associées |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200124624A1 (fr) |
| EP (1) | EP3433623A2 (fr) |
| JP (2) | JP6940515B2 (fr) |
| KR (1) | KR20180124971A (fr) |
| AU (1) | AU2017238769A1 (fr) |
| CA (1) | CA3018745A1 (fr) |
| IL (1) | IL261906A (fr) |
| MA (1) | MA44484A (fr) |
| MX (1) | MX2018011679A (fr) |
| WO (1) | WO2017165766A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201803553D0 (en) | 2018-03-06 | 2018-04-18 | Univ Newcastle | Detection of pathological protein aggregation |
| SG11202108502UA (en) | 2019-02-04 | 2021-09-29 | Freeline Therapeutics Ltd | Polynucleotides |
| WO2021173962A1 (fr) * | 2020-02-28 | 2021-09-02 | Genemo, Inc. | Méthodes et matériaux pour le diagnostic et le traitement d'un trouble neuronal |
| CN116420078A (zh) * | 2020-10-14 | 2023-07-11 | 戴纳立制药公司 | 用于治疗和监测额颞痴呆的方法 |
| CN112798727B (zh) * | 2021-04-09 | 2021-07-06 | 宝枫生物科技(北京)有限公司 | 用于诊断脑白质病变的生物标志物f7及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8781557B2 (en) | 1999-08-11 | 2014-07-15 | Osteoplastics, Llc | Producing a three dimensional model of an implant |
| WO2001097829A2 (fr) * | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Traitement de substitution enzymatique, therapie genique et therapie par petites molecules pour maladies liees au stockage lysosomal |
| WO2005080594A2 (fr) | 2004-02-24 | 2005-09-01 | Innogenetics N.V. | Methode de determination des risques qu'a un sujet de contracter une maladie neurologique |
| GB2414309B (en) | 2004-05-18 | 2009-02-25 | Simon Richard Daniel | Spherical display and control device |
| US20080248512A1 (en) | 2006-09-12 | 2008-10-09 | Genzyme Corporation | Methods for detection of lysosomal storage disease |
| US8304447B2 (en) | 2007-05-31 | 2012-11-06 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| US8026099B2 (en) | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
| US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
| EP2361089A4 (fr) * | 2008-11-14 | 2012-08-22 | Parkinson S Inst | Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine |
| EP2596133A4 (fr) * | 2010-07-23 | 2014-04-23 | Harvard College | Méthodes de dépistage de maladies ou d'affections neurologiques ou neuropsychiatriques |
| MY173998A (en) | 2011-03-18 | 2020-03-03 | Genzyme Corp | Glucosylceramide synthase inhibitors |
| CN103764166B (zh) * | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
| WO2013070953A1 (fr) | 2011-11-08 | 2013-05-16 | University Of Washington | Procédés et compositions d'analyse d'enzymes lysosomales |
-
2017
- 2017-03-24 JP JP2018549853A patent/JP6940515B2/ja active Active
- 2017-03-24 WO PCT/US2017/024012 patent/WO2017165766A2/fr not_active Ceased
- 2017-03-24 CA CA3018745A patent/CA3018745A1/fr not_active Abandoned
- 2017-03-24 EP EP17717568.4A patent/EP3433623A2/fr active Pending
- 2017-03-24 MX MX2018011679A patent/MX2018011679A/es unknown
- 2017-03-24 KR KR1020187030559A patent/KR20180124971A/ko not_active Withdrawn
- 2017-03-24 AU AU2017238769A patent/AU2017238769A1/en not_active Abandoned
- 2017-03-24 MA MA044484A patent/MA44484A/fr unknown
- 2017-03-24 US US16/088,031 patent/US20200124624A1/en active Pending
-
2018
- 2018-09-20 IL IL261906A patent/IL261906A/en unknown
-
2021
- 2021-09-02 JP JP2021142850A patent/JP7250081B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3018745A1 (fr) | 2017-09-28 |
| IL261906A (en) | 2018-10-31 |
| KR20180124971A (ko) | 2018-11-21 |
| JP2019513231A (ja) | 2019-05-23 |
| MX2018011679A (es) | 2019-06-24 |
| JP6940515B2 (ja) | 2021-09-29 |
| JP7250081B2 (ja) | 2023-03-31 |
| JP2021185377A (ja) | 2021-12-09 |
| EP3433623A2 (fr) | 2019-01-30 |
| US20200124624A1 (en) | 2020-04-23 |
| WO2017165766A2 (fr) | 2017-09-28 |
| AU2017238769A1 (en) | 2018-11-15 |
| WO2017165766A3 (fr) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50502A (fr) | Adénovirus et utilisations associées | |
| EP3334706A4 (fr) | Pillararènes et utilisations de ceux-ci | |
| PT3667980T (pt) | Indicar e receber localização de recurso | |
| MA46700A (fr) | Variants polypeptidiques et ses utilisations | |
| EP3356558A4 (fr) | Biomarqueurs pathogènes et utilisations associées | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3453214A4 (fr) | Agencement de ressources | |
| EP3365686A4 (fr) | Sondes réactives à la cystéine et utilisations associées | |
| EP3408402A4 (fr) | Détection magnéto-électrochimique | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| EP3509589A4 (fr) | Nouvelles utilisations | |
| EP3341387A4 (fr) | Inhibiteurs de sialyltransférase et utilisations de ceux-ci | |
| EP3538261A4 (fr) | Catalyseurs en pérovskite et leurs utilisations | |
| EP3350181A4 (fr) | Ligands her3 et utilisations de ceux-ci | |
| EP3347021A4 (fr) | Cyano-thiénotriazoloazépines et leurs utilisations | |
| EP3517118A4 (fr) | Activateur de sperme et utilisations associées | |
| MA43957A (fr) | Biomarqueurs de copanlisib | |
| EP3450444A4 (fr) | Composés de type crocine et utilisations correspondantes | |
| MA41022A (fr) | Ciblage lysosomial et utilisations correspondantes | |
| MA43958A (fr) | Biomarqueurs copanlisib | |
| EP3402879A4 (fr) | Lubrifiant modifié | |
| EP3459937A4 (fr) | Dérivé de thiazole et utilisations | |
| EP3665994A4 (fr) | Définition de ressources | |
| PT3365321T (pt) | Zwiterião de solabegron e suas utilizações | |
| PT3337506T (pt) | Combinações e suas utilizações |